61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
AstraZeneca PLC
Closed
Sector Healthcare
10,264 0.33
Overview
Share price change
24h
Min
10080
Max
10274
Income | -498M 1.4B |
|---|---|
Sales | 632M 14B |
P/E Sector Avg | 37.64 87.008 |
EPS | 2.08 |
Dividend yield | 2.016 |
Profit margin | 10.531 |
EBITDA | 548M 4.7B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +34.22 upside |
Dividend yield Sector Avg | 2.02% 2.48% |
|---|---|
Next Earnings | 6 Feb 2025 |
Next Ex Dividend date | 20 Feb 2025 |
Market Cap | -527M 164B |
|---|---|
Previous open | 10263.67 |
Previous close | 10264 |
News Sentiment
By Acuity
55%
45%
327 / 392 Healthcare
AstraZeneca PLC Chart
Past performance is not a reliable indicator of future results.
Related News
AstraZeneca PLC Forecast
Price Target
By TipRanks
34.22% upside
12 Months Forecast
Average 13,765.5 GBX 34.22%
High 18,000 GBX
Low 10,500 GBX
Based on 14 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.
Sentiment
By Acuity
327 / 392 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AstraZeneca PLC
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.